OR WAIT null SECS
Ginko will be eligible for up to $331 million in milestone payments.
Ginko Bioworks and Pfizer have officially announced a partnership focused on the discovery of RNA-based drug candidates, with the pharma giant leveraging Ginko’s proprietary RNA technology to advance development of novel RNA molecules across priority research areas. After receiving an upfront payment, Ginko will also be eligible for additional payments of up to $331 million contingent upon achievement development and commercial milestone.
"Billions of patients around the world have already benefited from advances in RNA-based technologies. We're thrilled to be able to help enable the discovery and development of novel drugs using this powerful modality by applying our platform technologies, which are designed to program RNA for maximum therapeutic effect," said Jason Kelly, CEO, co-founder, Ginkgo Bioworks. "Ginkgo's approach enables and accelerates discovery across different disease areas and modalities for our partners, who bring deep expertise in drug development. We can't wait to leverage our broad and deep RNA Codebase and deploy our Foundry to enable the era of programmable medicines with the Pfizer team."
Reference: Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer. PR Newswire. September 27, 2023. Accessed September 27, 2023. https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-multi-target-rna-discovery-collaboration-with-pfizer-301939570.html